Drug Trial Radar · NCT06555419
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Jan 16, 2025
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Alcyone Therapeutics, Inc
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this PIERRE-PK study, researchers will learn how the body processes nusinersen when it is given through the ThecaFlex DRx™ System, compared to when nusinersen is given by lumbar puncture (LP). The ThecaFlex DRx system is an investigational implantable medical device developed by Alcyone Therapeutics, Inc. It consists of a catheter, which is a flexible tube, connected to a port which is placed under the skin. Alcyone Therapeutics, Inc. has an ongoing study called PIERRE to test the ThecaFlex DRx system. Participants with spinal muscular atrophy (SMA) in the PIERRE study may be enrolled in the PIERRE-PK study. The main goal of the PIERRE-PK study is to learn how the body processes nusinersen when given by the ThecaFlex DRx system compared to a lumbar puncture. The main questions researchers want to answer are: * What is the highest amount of nusinersen found in the blood after dosing? * How much nusinersen is found in the blood over the first 24 hours after dosing? The PIERRE-PK study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 30 days for this study and may overlap with the PIERRE study. * Participants will join 1 of 2 groups based on their ongoing nusinersen treatment. One group will be receiving 12 mg doses of nusinersen. The other group will be receiving 28 mg doses of nusinersen. * Participants will first receive a dose of nusinersen by lumbar puncture. * The ThecaFlex DRx system will be implanted after the lumbar puncture, as part of the PIERRE study. * Participants will receive a dose of nusinersen by the ThecaFlex DRx system, as part of the PIERRE study. This dose will be a regular maintenance dose that happens about 4 months after their first dose in this study. * Researchers will take blood samples before and after each dose. The last blood sample will be taken 24 hours after the dose. * The total study duration for each participant in the PIERRE-PK study will be approximately 5 months. This period will overlap with the participant's first 5 months in the PIERRE study.
Conditions
- Muscular Atrophy, Spinal
Interventions
NusinersenDrug
Administered as specified in the treatment arm.
ThecaFlex DRx SystemDevice
Implanted as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Concentration (Cmax) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx SystemTime frame: Pre-dose and at multiple time points post-dose over 4 months
- Area Under the Plasma Concentration-Time Curve From Zero Time to 24 Hours After Intrathecal Administration (AUC0-24h) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx SystemTime frame: Pre-dose and at multiple time points post-dose over 4 months
Locations
21 sites in 7 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute
Phoenix, Arizona · Recruiting
Children's Hospital of Orange County
Orange, California · Recruiting
Stanford University Medical Center | Department of Neurology_Palo Alto
Palo Alto, California · Recruiting
Nemours Children's Hospital, Orlando
Orlando, Florida · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Helen DeVos Children's Hospita
Grand Rapids, Michigan · Recruiting
Milton S. Hershey Medical Center | Pennsylvania State University_Hershey
Hershey, Pennsylvania · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Texas Childrens Hospital Houston
Houston, Texas · Recruiting
Stacey Hall Developmental Pediatrics
Charlottesville, Virginia · Recruiting
Children's Hospital of the King's Daughters_Norfolk
Norfolk, Virginia · Recruiting
Hôpital Raymond Poincaré
Garches, Hauts De Seine, France · Recruiting
Universitaetsklinikum Essen
Essen, Germany · Recruiting
Fondazione Serena Onlus - Centro Clinico Nemo_Milano
Milan, Italy · Withdrawn
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Withdrawn
Szpital Specjalistyczny im. L.Rydygiera w Krakowie
Krakow, Poland · Recruiting
Instytut Centrum Zdrowia Matki Polki
Lodz, Poland · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Hospital Universitari i Politecnic La Fe_Valencia
Valencia, Spain · Recruiting
Royal Hallamshire Hospital Neurology Department
Sheffield, South Yorkshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.